"","Country.Name","Country.Code","Region","continent","GNI_per_c_WB","year_GNI","q_GNI_per_c_WB","Income group","min_vac_intro","min_vac_intro_owid_or_who","owid_vac_F40","owid_vac_F70","vaccines","mRNA","Vectored","Inactivated","Protein","min_VE_pub_date","n_VE_studies","...1","vac_intro_hcw","vac_F40_hcw","vac_F70_hcw","vac_intro_old","vac_F40_old","vac_F70_old"
"1","Aruba","ABW","Latin America & Caribbean","North America",28720,2019,4,"High income",2021-02-17,"who",2021-05-22,2021-09-27,"Pfizer/BioNTech",1,0,0,0,NA,NA,1,NA,NA,NA,2022-03-01,2022-03-01,2022-03-01
"2","Afghanistan","AFG","South Asia","Asia",520,2019,1,"Low income",2021-02-22,"who",2023-06-20,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,2,2021-03-01,2023-03-01,NA,2022-08-01,2022-09-01,NA
"3","Angola","AGO","Sub-Saharan Africa","Africa",2110,2019,1,"Lower middle income",2021-03-08,"owid",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,3,NA,NA,NA,NA,NA,NA
"4","Albania","ALB","Europe & Central Asia","Europe",5280,2019,2,"Upper middle income",2021-01-13,"equal",2022-02-01,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V",1,1,1,0,2023-05-05,1,4,2021-01-01,2021-01-01,2022-03-01,2021-01-01,2021-01-01,2021-01-01
"5","Andorra","AND","Europe & Central Asia","Europe",46450,2019,4,"High income",2021-01-20,"who",2021-07-19,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,5,2021-01-01,NA,NA,2021-01-01,2021-01-01,2021-01-01
"6","United Arab Emirates","ARE","Middle East & North Africa","Asia",45070,2019,4,"High income",2021-01-05,"owid",2021-04-20,2021-07-15,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,2021-10-27,2,6,NA,NA,NA,NA,NA,NA
"7","Argentina","ARG","Latin America & Caribbean","South America",11210,2019,3,"Upper middle income",2020-12-29,"equal",2021-09-18,2022-01-14,"CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,2022-03-15,3,7,2021-03-01,2021-03-01,2021-04-01,2021-03-01,2021-07-01,2021-08-01
"8","Armenia","ARM","Europe & Central Asia","Asia",4650,2019,2,"Upper middle income",2021-01-27,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,8,2022-01-01,2022-01-01,NA,2022-01-01,2022-01-01,NA
"9","Antigua and Barbuda","ATG","Latin America & Caribbean","North America",18240,2019,3,"High income",2021-03-01,"who",2021-09-24,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,9,NA,NA,NA,NA,NA,NA
"10","Australia","AUS","East Asia & Pacific","Oceania",54890,2019,4,"High income",2021-02-21,"who",2021-09-24,2021-11-21,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2023-07-29,1,10,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"11","Austria","AUT","Europe & Central Asia","Europe",51050,2019,4,"High income",2020-12-30,"who",2021-07-09,2021-12-24,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK, Valneva",1,1,1,1,NA,NA,11,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"12","Azerbaijan","AZE","Europe & Central Asia","Asia",4510,2019,2,"Upper middle income",2021-01-20,"who",2021-10-14,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V",1,1,1,0,NA,NA,12,NA,NA,NA,NA,NA,NA
"13","Burundi","BDI","Sub-Saharan Africa","Africa",220,2019,1,"Low income",2021-10-18,"who",NA,NA,"Johnson&Johnson, Sinopharm/Beijing",0,1,1,0,NA,NA,13,2022-04-01,NA,NA,NA,NA,NA
"14","Belgium","BEL","Europe & Central Asia","Europe",48050,2019,4,"High income",2020-12-30,"equal",2021-07-08,2021-08-30,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2022-05-11,2,14,2021-01-01,2021-01-01,2021-11-01,2021-01-01,2021-01-01,2021-01-01
"15","Benin","BEN","Sub-Saharan Africa","Africa",1170,2019,1,"Lower middle income",2021-03-29,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,15,2022-03-01,2022-03-01,2022-03-01,2022-03-01,NA,NA
"16","Burkina Faso","BFA","Sub-Saharan Africa","Africa",750,2019,1,"Low income",2021-06-02,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,16,2021-11-01,2021-11-01,2022-11-01,2023-01-01,2023-01-01,NA
"17","Bangladesh","BGD","South Asia","Asia",2220,2019,2,"Lower middle income",2021-01-27,"who",2022-02-18,2022-07-16,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,2022-12-02,1,17,NA,NA,NA,2022-02-01,2022-02-01,NA
"18","Bulgaria","BGR","Europe & Central Asia","Europe",9440,2019,3,"Upper middle income",2020-12-29,"owid",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,18,2021-01-01,2021-01-01,NA,2021-01-01,2021-01-01,2021-01-01
"19","Bahrain","BHR","Middle East & North Africa","Asia",25800,2019,4,"High income",2020-11-04,"who",2021-05-11,2021-07-17,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,19,NA,NA,NA,NA,NA,NA
"20","Bahamas, The","BHS","Latin America & Caribbean","North America",30960,2019,4,"High income",2021-03-14,"equal",2022-09-16,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,20,NA,NA,NA,2022-05-01,2022-05-01,NA
"21","Bosnia and Herzegovina","BIH","Europe & Central Asia","Europe",6180,2019,2,"Upper middle income",2021-04-14,"owid",NA,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V",1,1,1,0,NA,NA,21,2021-04-01,NA,NA,2021-04-01,NA,NA
"22","Belarus","BLR","Europe & Central Asia","Europe",6370,2019,2,"Upper middle income",2021-02-03,"who",2022-01-16,NA,"KoviVac/Chumakov, Sinopharm/Beijing, Sputnik Light, Sputnik V",0,1,1,0,NA,NA,22,2021-03-01,2021-12-01,2021-12-01,NA,NA,NA
"23","Belize","BLZ","Latin America & Caribbean","North America",5870,2019,2,"Upper middle income",2021-03-01,"who",2021-11-12,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,23,2021-03-01,2021-06-01,NA,2022-01-01,2022-01-01,2023-05-01
"24","Bermuda","BMU","North America","North America",116920,2019,4,"High income",2021-01-11,"who",2021-05-12,2021-12-10,"Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,24,NA,NA,NA,NA,NA,NA
"25","Bolivia","BOL","Latin America & Caribbean","South America",3470,2019,2,"Lower middle income",2021-01-30,"who",2022-01-14,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,25,2021-05-01,2021-05-01,2021-05-01,2021-05-01,2021-08-01,2021-11-01
"26","Brazil","BRA","Latin America & Caribbean","South America",9410,2019,3,"Upper middle income",2021-01-17,"who",2021-09-24,2022-02-05,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,2021-07-21,17,26,2021-05-01,2022-01-01,2022-01-01,2021-05-01,2021-05-01,2022-01-01
"27","Barbados","BRB","Latin America & Caribbean","North America",19490,2019,3,"High income",2021-01-08,"who",2021-10-11,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,27,NA,NA,NA,NA,NA,NA
"28","Brunei Darussalam","BRN","East Asia & Pacific","Asia",31550,2019,4,"High income",2021-04-03,"equal",2021-09-28,2021-11-19,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,28,2021-10-01,2021-10-01,2021-10-01,2021-04-01,2021-09-01,2021-10-01
"29","Bhutan","BTN","South Asia","Asia",3370,2019,2,"Lower middle income",2021-03-27,"equal",2021-07-23,2021-10-31,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,29,2022-05-01,2022-05-01,2022-05-01,2022-05-01,2022-05-01,2022-05-01
"30","Botswana","BWA","Sub-Saharan Africa","Africa",7520,2019,3,"Upper middle income",2021-03-26,"who",2022-01-17,NA,"Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,30,2021-11-01,2021-11-01,2021-11-01,2021-11-01,2021-11-01,2021-11-01
"31","Central African Republic","CAF","Sub-Saharan Africa","Africa",500,2019,1,"Low income",2021-03-19,"who",2023-03-05,NA,"Covaxin, Oxford/AstraZeneca",0,1,1,0,NA,NA,31,2022-10-01,2022-10-01,2022-10-01,2022-12-01,2022-12-01,2022-12-01
"32","Canada","CAN","North America","North America",46580,2019,4,"High income",2020-12-14,"who",2021-07-09,2021-09-28,"Johnson&Johnson, Medicago, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2021-07-09,28,32,NA,NA,NA,2021-03-01,2021-06-01,2021-07-01
"33","Switzerland","CHE","Europe & Central Asia","Europe",83160,2019,4,"High income",2020-12-23,"who",NA,NA,"Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech",1,1,0,1,NA,NA,33,2021-02-01,2021-05-01,NA,2021-01-01,2021-01-01,2021-01-01
"34","Chile","CHL","Latin America & Caribbean","South America",14690,2019,3,"High income",2020-12-21,"who",2021-05-25,2021-09-02,"CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,2021-07-07,5,34,2021-03-01,2021-03-01,2021-03-01,2021-03-01,2021-03-01,2021-03-01
"35","China","CHN","East Asia & Pacific","Asia",10310,2019,3,"Upper middle income",2020-07-22,"who",2021-08-12,2021-09-15,"CanSino, IMBCAMS, KCONVAC, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001",0,1,1,1,2022-01-10,5,35,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"36","Cote d'Ivoire","CIV","Sub-Saharan Africa","Africa",2120,2019,1,"Lower middle income",2021-03-01,"who",2022-12-18,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,36,2021-03-01,NA,NA,2021-10-01,2022-02-01,2022-10-01
"37","Cameroon","CMR","Sub-Saharan Africa","Africa",1560,2019,1,"Lower middle income",2021-04-12,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,37,2021-10-01,2022-09-01,NA,2021-10-01,NA,NA
"38","Congo, Dem. Rep.","COD","Sub-Saharan Africa","Africa",490,2019,1,"Low income",2021-04-19,"who",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,38,2021-11-01,2022-09-01,2022-12-01,2021-11-01,2023-03-01,NA
"39","Congo, Rep.","COG","Sub-Saharan Africa","Africa",2180,2019,2,"Lower middle income",2021-03-23,"who",NA,NA,"Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,39,NA,NA,NA,NA,NA,NA
"40","Colombia","COL","Latin America & Caribbean","South America",6630,2019,3,"Upper middle income",2021-02-17,"who",2021-10-26,2022-07-29,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,2021-10-19,6,40,2021-07-01,2021-07-01,2021-07-01,2021-07-01,2021-07-01,2021-07-01
"41","Comoros","COM","Sub-Saharan Africa","Africa",1530,2019,1,"Lower middle income",2021-04-10,"who",2022-07-03,NA,"Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,41,2021-11-01,2021-11-01,2021-11-01,2022-04-01,2023-01-01,2023-01-01
"42","Cabo Verde","CPV","Sub-Saharan Africa","Africa",4420,2019,2,"Lower middle income",2021-03-18,"who",2021-11-26,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,42,2021-10-01,2021-10-01,2021-10-01,2021-10-01,2021-10-01,NA
"43","Costa Rica","CRI","Latin America & Caribbean","North America",12240,2019,3,"Upper middle income",2020-12-24,"who",2021-09-27,2022-01-17,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,43,2021-03-01,2021-03-01,2021-03-01,2021-03-01,2021-07-01,2021-07-01
"44","Cuba","CUB","Latin America & Caribbean","North America",9010,2019,3,"Upper middle income",2021-05-31,"owid",2021-09-18,2021-11-09,"Abdala, Soberana Plus, Soberana02",0,0,0,1,2022-09-28,1,44,2023-12-01,2023-12-01,2023-12-01,NA,NA,NA
"45","Curacao","CUW","Latin America & Caribbean","North America",19140,2019,3,"High income",2021-03-29,"owid",2021-06-21,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,45,NA,NA,NA,NA,NA,NA
"46","Cayman Islands","CYM","Latin America & Caribbean","North America",64520,2019,4,"High income",2021-01-15,"who",2021-04-20,2021-08-06,"Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,46,NA,NA,NA,NA,NA,NA
"47","Cyprus","CYP","Europe & Central Asia","Europe",28840,2019,4,"High income",2020-12-23,"who",2021-07-02,2022-01-31,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,47,2021-01-01,NA,NA,2021-01-01,2021-01-01,2021-01-01
"48","Czechia","CZE","Europe & Central Asia","Europe",22100,2019,3,"High income",2020-12-23,"who",2021-07-16,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,1,2021-12-12,4,48,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"49","Germany","DEU","Europe & Central Asia","Europe",49470,2019,4,"High income",2020-12-23,"who",2021-07-06,2021-12-18,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Valneva",1,1,1,1,2021-09-09,1,49,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"50","Djibouti","DJI","Middle East & North Africa","Africa",2780,2019,2,"Lower middle income",2021-03-15,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,50,NA,NA,NA,NA,NA,NA
"51","Dominica","DMA","Latin America & Caribbean","North America",8690,2019,3,"Upper middle income",2021-02-12,"who",2022-02-02,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,51,2021-07-01,NA,NA,2021-07-01,2021-07-01,2023-12-01
"52","Denmark","DNK","Europe & Central Asia","Europe",63020,2019,4,"High income",2020-12-16,"who",2021-07-16,2021-09-03,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,2021-03-09,8,52,2021-01-01,2021-01-01,2021-07-01,2021-01-01,2021-01-01,2021-01-01
"53","Dominican Republic","DOM","Latin America & Caribbean","North America",7980,2019,3,"Upper middle income",2021-02-16,"who",2021-08-18,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,NA,NA,53,NA,NA,NA,NA,NA,NA
"54","Algeria","DZA","Middle East & North Africa","Africa",4480,2019,2,"Lower middle income",2021-01-30,"who",NA,NA,"Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V",0,1,1,0,NA,NA,54,NA,NA,NA,NA,NA,NA
"55","Ecuador","ECU","Latin America & Caribbean","South America",6100,2019,2,"Upper middle income",2021-01-20,"who",2021-08-23,2021-12-28,"CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,55,2021-06-01,2021-06-01,2021-06-01,2021-06-01,2021-08-01,2021-10-01
"56","Egypt, Arab Rep.","EGY","Middle East & North Africa","Africa",2640,2019,2,"Lower middle income",2021-01-24,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,2022-03-11,1,56,NA,NA,NA,NA,NA,NA
"57","Eritrea","ERI","Sub-Saharan Africa",NA,650,2011,1,"Low income",NA,"no date",NA,NA,NA,NA,NA,NA,NA,NA,NA,57,NA,NA,NA,NA,NA,NA
"58","Spain","ESP","Europe & Central Asia","Europe",30370,2019,4,"High income",2020-12-30,"who",2021-07-04,2021-08-31,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,2021-04-29,9,58,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"59","Estonia","EST","Europe & Central Asia","Europe",23060,2019,4,"High income",2020-12-23,"who",2021-07-19,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,59,2021-01-01,2021-05-01,NA,2021-01-01,2021-01-01,2021-01-01
"60","Ethiopia","ETH","Sub-Saharan Africa","Africa",820,2019,1,"Low income",2021-03-13,"who",NA,NA,"Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac",0,1,1,0,NA,NA,60,2021-10-01,2021-10-01,NA,2021-10-01,2022-02-01,2022-07-01
"61","Finland","FIN","Europe & Central Asia","Europe",49950,2019,4,"High income",2020-12-23,"who",2021-08-15,2021-10-31,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,2021-06-28,4,61,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"62","Fiji","FJI","East Asia & Pacific","Oceania",5620,2019,2,"Upper middle income",2021-03-07,"who",2021-09-21,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,62,2021-11-01,2021-11-01,2021-11-01,2021-11-01,2021-11-01,2021-11-01
"63","France","FRA","Europe & Central Asia","Europe",42470,2019,4,"High income",2020-12-23,"who",2021-07-15,2021-12-03,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK",1,1,0,1,2021-07-31,6,63,2021-03-01,2021-05-01,NA,2021-01-01,2021-01-01,2021-01-01
"64","Faroe Islands","FRO","Europe & Central Asia","Europe",66010,2019,4,"High income",2021-01-29,"owid",2021-07-07,2021-10-19,"Moderna, Pfizer/BioNTech",1,0,0,0,NA,NA,64,NA,NA,NA,NA,NA,NA
"65","Gabon","GAB","Sub-Saharan Africa","Africa",6870,2019,3,"Upper middle income",2021-03-23,"who",NA,NA,"Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,65,2023-02-01,2023-02-01,NA,2023-02-01,2023-03-01,2023-03-01
"66","United Kingdom","GBR","Europe & Central Asia","Europe",43240,2019,4,"High income",2020-12-21,"who",2021-06-04,2021-12-23,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,2021-02-21,48,66,NA,NA,NA,NA,NA,NA
"67","Georgia","GEO","Europe & Central Asia","Asia",4780,2019,2,"Upper middle income",2021-03-17,"who",NA,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,NA,NA,67,2021-03-01,2021-09-01,NA,2021-03-01,2022-01-01,NA
"68","Ghana","GHA","Sub-Saharan Africa","Africa",2170,2019,1,"Lower middle income",2021-03-02,"who",NA,NA,"Oxford/AstraZeneca, Sputnik V",0,1,0,0,NA,NA,68,2021-12-01,2021-12-01,NA,2021-10-01,2023-03-01,2023-03-01
"69","Guinea","GIN","Sub-Saharan Africa","Africa",970,2019,1,"Lower middle income",2021-03-05,"who",2023-09-24,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V",1,1,1,0,NA,NA,69,2022-02-01,2022-02-01,2023-01-01,2022-02-01,2022-02-01,NA
"70","Gambia, The","GMB","Sub-Saharan Africa","Africa",720,2019,1,"Low income",2021-03-10,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,70,2021-10-01,2021-10-01,2021-10-01,2021-10-01,NA,NA
"71","Guinea-Bissau","GNB","Sub-Saharan Africa","Africa",850,2019,1,"Low income",2021-04-02,"who",NA,NA,"Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,71,2022-01-01,2022-01-01,2022-01-01,2022-01-01,2022-07-01,2023-01-01
"72","Equatorial Guinea","GNQ","Sub-Saharan Africa","Africa",5130,2019,2,"Upper middle income",2021-02-12,"who",NA,NA,"Sinopharm/Beijing, Sinovac",0,0,1,0,NA,NA,72,2021-02-01,2021-02-01,2021-02-01,NA,NA,NA
"73","Greece","GRC","Europe & Central Asia","Europe",19690,2019,3,"High income",2020-12-23,"who",2021-07-09,2022-01-24,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2022-01-29,1,73,2021-02-01,2021-02-01,2021-05-01,2021-02-01,2021-05-01,2021-06-01
"74","Grenada","GRD","Latin America & Caribbean","North America",9400,2019,3,"Upper middle income",2021-02-15,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,74,2021-05-01,NA,NA,NA,NA,NA
"75","Greenland","GRL","Europe & Central Asia","North America",34800,2007,4,"High income",2021-01-27,"owid",2021-07-28,NA,"Moderna",1,0,0,0,NA,NA,75,NA,NA,NA,NA,NA,NA
"76","Guatemala","GTM","Latin America & Caribbean","North America",4490,2019,2,"Upper middle income",2021-02-25,"who",NA,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V",1,1,0,0,NA,NA,76,2021-04-01,2021-05-01,2021-06-01,2021-05-01,2021-09-01,NA
"77","Guyana","GUY","Latin America & Caribbean","South America",6380,2019,2,"High income",2021-02-11,"who",2022-02-19,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,77,NA,NA,NA,2022-03-01,2022-03-01,2022-08-01
"78","Hong Kong SAR, China","HKG","East Asia & Pacific","Asia",50480,2019,4,"High income",2021-02-23,"owid",2021-08-19,2022-03-04,"Pfizer/BioNTech, Sinovac",1,0,1,0,2022-08-11,12,78,NA,NA,NA,2021-07-01,2021-09-01,2022-03-01
"79","Honduras","HND","Latin America & Caribbean","North America",2330,2019,2,"Lower middle income",2021-02-22,"who",2021-12-29,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V",1,1,0,0,NA,NA,79,2021-03-01,2021-06-01,2021-06-01,2021-07-01,2021-10-01,NA
"80","Croatia","HRV","Europe & Central Asia","Europe",15800,2019,3,"High income",2020-12-23,"who",2021-09-01,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,80,2021-01-01,2021-01-01,2022-02-01,2021-01-01,2021-01-01,2021-01-01
"81","Haiti","HTI","Latin America & Caribbean","North America",1410,2019,1,"Lower middle income",2021-07-21,"owid",NA,NA,"Johnson&Johnson, Moderna",1,1,0,0,NA,NA,81,NA,NA,NA,NA,NA,NA
"82","Hungary","HUN","Europe & Central Asia","Europe",16570,2019,3,"High income",2020-12-23,"who",2021-06-05,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,2021-11-24,3,82,2021-01-01,2021-01-01,2021-05-01,2021-01-01,2021-01-01,2021-01-01
"83","Indonesia","IDN","East Asia & Pacific","Asia",4020,2019,2,"Upper middle income",2021-01-13,"who",2021-12-25,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,1,2022-02-03,1,83,2021-04-01,2021-04-01,2021-04-01,2021-04-01,2022-02-01,NA
"84","Isle of Man","IMN","Europe & Central Asia","Europe",84470,2019,4,"High income",2021-01-21,"owid",2021-06-22,2021-08-02,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,84,NA,NA,NA,NA,NA,NA
"85","India","IND","South Asia","Asia",2070,2019,1,"Lower middle income",2021-01-16,"equal",2021-12-24,NA,"Corbevax, Covaxin, Novavax, Oxford/AstraZeneca, Sputnik V",0,1,1,1,2021-11-23,4,85,2021-04-01,2021-04-01,2021-04-01,2021-04-01,2022-02-01,2022-02-01
"86","Ireland","IRL","Europe & Central Asia","Europe",63590,2019,4,"High income",2020-12-28,"owid",2021-07-04,2021-09-06,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,86,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"87","Iran, Islamic Rep.","IRN","Middle East & North Africa","Asia",4530,2019,2,"Lower middle income",2021-02-09,"who",2021-11-02,NA,"COVIran Barekat, CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V",1,1,1,1,2022-12-23,1,87,2021-05-01,2021-05-01,2021-05-01,2021-05-01,2021-08-01,2021-08-01
"88","Iraq","IRQ","Middle East & North Africa","Asia",5520,2019,2,"Upper middle income",2021-03-02,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,88,2022-03-01,2022-03-01,NA,2022-11-01,NA,NA
"89","Iceland","ISL","Europe & Central Asia","Europe",75160,2019,4,"High income",2020-12-30,"equal",2021-06-17,2021-08-25,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,89,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"90","Israel","ISR","Middle East & North Africa","Asia",43800,2019,4,"High income",2020-12-16,"who",2021-03-07,NA,"Moderna, Pfizer/BioNTech",1,0,0,0,2021-02-18,30,90,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"91","Italy","ITA","Europe & Central Asia","Europe",34890,2019,4,"High income",2020-12-23,"who",2021-07-12,2021-10-04,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK",1,1,0,1,2021-04-29,13,91,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"92","Jamaica","JAM","Latin America & Caribbean","North America",5480,2019,2,"Upper middle income",2021-03-10,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,92,2021-06-01,2021-10-01,NA,2021-06-01,NA,NA
"93","Jordan","JOR","Middle East & North Africa","Asia",4190,2019,2,"Lower middle income",2021-01-13,"who",2022-06-27,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,93,2022-11-01,2022-11-01,2022-11-01,2022-11-01,2022-11-01,NA
"94","Japan","JPN","East Asia & Pacific","Asia",41970,2019,4,"High income",2021-02-17,"who",2021-08-11,2021-10-16,"Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2022-08-03,5,94,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"95","Kazakhstan","KAZ","Europe & Central Asia","Asia",8500,2019,3,"Upper middle income",2021-02-11,"owid",2021-11-12,NA,"QazVac, Sinopharm/Beijing, Sputnik V",0,1,1,0,NA,NA,95,2021-02-01,NA,NA,NA,NA,NA
"96","Kenya","KEN","Sub-Saharan Africa","Africa",1880,2019,1,"Lower middle income",2021-03-05,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,96,2021-10-01,2021-11-01,NA,2021-10-01,NA,NA
"97","Kyrgyz Republic","KGZ","Europe & Central Asia","Asia",1240,2019,1,"Lower middle income",2021-03-31,"who",NA,NA,"Sinopharm/Beijing, Sputnik V",0,1,1,0,NA,NA,97,2021-03-01,2021-06-01,NA,2021-03-01,NA,NA
"98","Cambodia","KHM","East Asia & Pacific","Asia",2100,2019,1,"Lower middle income",2021-02-10,"who",2021-08-12,2021-10-12,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,NA,NA,98,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"99","Kiribati","KIR","East Asia & Pacific","Oceania",3610,2019,2,"Lower middle income",2021-05-26,"who",2022-03-21,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,99,2021-08-01,2022-01-01,2022-09-01,2021-08-01,2021-12-01,2022-01-01
"100","St. Kitts and Nevis","KNA","Latin America & Caribbean","North America",23660,2019,4,"High income",2021-02-22,"who",2021-07-13,NA,"Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,100,NA,NA,NA,NA,NA,NA
"101","Korea, Rep.","KOR","East Asia & Pacific","Asia",33830,2019,4,"High income",2021-02-26,"equal",2021-09-15,2021-10-25,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2022-08-17,3,101,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"102","Kuwait","KWT","Middle East & North Africa","Asia",35680,2019,4,"High income",2020-12-28,"equal",2021-11-30,2021-11-30,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,2021-07-29,2,102,NA,NA,NA,NA,NA,NA
"103","Lao PDR","LAO","East Asia & Pacific","Asia",2520,2019,2,"Lower middle income",2020-11-25,"who",2021-11-23,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,103,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"104","Lebanon","LBN","Middle East & North Africa","Asia",8630,2019,3,"Lower middle income",2021-02-14,"who",2022-03-24,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,2022-09-22,1,104,2022-11-01,2022-11-01,2022-11-01,2022-11-01,2022-11-01,NA
"105","Liberia","LBR","Sub-Saharan Africa","Africa",600,2019,1,"Low income",2021-04-01,"who",2022-06-26,2022-12-11,"Oxford/AstraZeneca",0,1,0,0,NA,NA,105,2022-05-01,2022-10-01,NA,2022-10-01,NA,NA
"106","Libya","LBY","Middle East & North Africa","Africa",10100,2019,3,"Upper middle income",2021-04-11,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,106,NA,NA,NA,NA,NA,NA
"107","St. Lucia","LCA","Latin America & Caribbean","North America",11100,2019,3,"Upper middle income",2021-02-17,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,107,NA,NA,NA,NA,NA,NA
"108","Liechtenstein","LIE","Europe & Central Asia","Europe",116380,2009,4,"High income",2021-01-04,"owid",NA,NA,"Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech",1,1,0,1,NA,NA,108,NA,NA,NA,NA,NA,NA
"109","Sri Lanka","LKA","South Asia","Asia",4220,2019,2,"Lower middle income",2021-01-29,"equal",2021-09-03,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,109,2021-08-01,2021-08-01,2021-08-01,2021-08-01,2022-06-01,2022-06-01
"110","Lesotho","LSO","Sub-Saharan Africa","Africa",1310,2019,1,"Lower middle income",2021-03-10,"who",2022-11-20,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,110,2021-10-01,2021-10-01,2021-10-01,2022-01-01,2022-01-01,2022-01-01
"111","Lithuania","LTU","Europe & Central Asia","Europe",19130,2019,3,"High income",2020-12-23,"who",2021-07-06,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,111,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"112","Luxembourg","LUX","Europe & Central Asia","Europe",79180,2019,4,"High income",2020-12-28,"owid",2023-06-11,2023-06-11,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,112,2021-01-01,2021-01-01,2021-10-01,2021-01-01,2021-01-01,2021-01-01
"113","Latvia","LVA","Europe & Central Asia","Europe",17580,2019,3,"High income",2020-12-28,"owid",2021-08-24,2022-02-16,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,113,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"114","Macao SAR, China","MAC","East Asia & Pacific","Asia",71920,2019,4,"High income",2021-02-09,"owid",2021-09-06,2022-02-21,"Pfizer/BioNTech, Sinopharm/Beijing",1,0,1,0,NA,NA,114,NA,NA,NA,NA,NA,NA
"115","Morocco","MAR","Middle East & North Africa","Africa",3510,2019,2,"Lower middle income",2021-01-28,"who",2021-08-31,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,2022-01-27,1,115,NA,NA,NA,NA,NA,NA
"116","Moldova","MDA","Europe & Central Asia","Europe",4490,2019,2,"Upper middle income",2021-03-03,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V",1,1,1,0,NA,NA,116,2021-03-01,2021-05-01,2021-07-01,2021-03-01,2022-11-01,NA
"117","Madagascar","MDG","Sub-Saharan Africa","Africa",490,2019,1,"Low income",2021-05-10,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,117,2021-08-01,2022-01-01,NA,2022-04-01,NA,NA
"118","Maldives","MDV","South Asia","Asia",10750,2019,3,"Upper middle income",2021-02-01,"who",2021-07-07,2021-12-22,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V",1,1,1,0,NA,NA,118,NA,NA,NA,2022-06-01,2022-06-01,2022-06-01
"119","Mexico","MEX","Latin America & Caribbean","North America",9860,2019,3,"Upper middle income",2020-12-24,"who",2021-10-18,NA,"CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V",1,1,1,0,2022-04-17,3,119,NA,NA,NA,2022-01-01,2022-01-01,2022-01-01
"120","North Macedonia","MKD","Europe & Central Asia","Europe",6520,2019,2,"Upper middle income",2021-02-17,"who",2022-06-19,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik V",1,1,1,0,NA,NA,120,2021-02-01,NA,NA,2021-02-01,2021-02-01,2021-02-01
"121","Mali","MLI","Sub-Saharan Africa","Africa",800,2019,1,"Low income",2021-03-31,"who",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,121,2021-10-01,2021-10-01,2021-11-01,2021-10-01,NA,NA
"122","Malta","MLT","Middle East & North Africa","Europe",29820,2019,4,"High income",2020-12-23,"who",2021-06-01,2021-07-27,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,122,2021-01-01,2021-01-01,2021-05-01,2021-01-01,2021-01-01,2021-01-01
"123","Myanmar","MMR","East Asia & Pacific","Asia",1380,2019,1,"Lower middle income",2021-01-27,"equal",2022-03-22,NA,"Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,123,NA,NA,NA,NA,NA,NA
"124","Montenegro","MNE","Europe & Central Asia","Europe",9140,2019,3,"Upper middle income",2021-02-24,"who",2021-11-20,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,124,2021-02-01,2021-02-01,NA,2021-02-01,2021-02-01,2021-02-01
"125","Mongolia","MNG","East Asia & Pacific","Asia",3800,2019,2,"Lower middle income",2021-02-23,"who",2021-06-02,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,125,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"126","Mozambique","MOZ","Sub-Saharan Africa","Africa",500,2019,1,"Low income",2021-03-08,"who",2022-10-16,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,126,2021-03-01,2021-03-01,NA,2021-10-01,2022-06-01,2022-06-01
"127","Mauritania","MRT","Sub-Saharan Africa","Africa",1720,2019,1,"Lower middle income",2021-03-26,"who",NA,NA,"Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,127,NA,NA,NA,NA,NA,NA
"128","Mauritius","MUS","Sub-Saharan Africa","Africa",12440,2019,3,"Upper middle income",2021-01-26,"who",2021-07-26,2021-12-28,"Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,128,NA,NA,NA,NA,NA,NA
"129","Malawi","MWI","Sub-Saharan Africa","Africa",540,2019,1,"Low income",2021-03-11,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca",0,1,0,0,NA,NA,129,2021-12-01,2021-12-01,2021-12-01,2021-12-01,NA,NA
"130","Malaysia","MYS","East Asia & Pacific","Asia",10750,2019,3,"Upper middle income",2021-02-24,"who",2021-08-24,2021-10-21,"CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,2022-01-16,3,130,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"131","Namibia","NAM","Sub-Saharan Africa","Africa",4870,2019,2,"Upper middle income",2021-03-19,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,131,2021-10-01,2021-10-01,2022-09-01,2023-01-01,NA,NA
"132","New Caledonia","NCL","East Asia & Pacific","Oceania",35550,2019,4,"High income",2021-01-20,"who",2021-10-12,NA,"Pfizer/BioNTech",1,0,0,0,NA,NA,132,NA,NA,NA,2021-01-01,2021-01-01,NA
"133","Niger","NER","Sub-Saharan Africa","Africa",610,2019,1,"Low income",2021-03-29,"who",NA,NA,"Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,133,2021-03-01,NA,NA,2021-04-01,NA,NA
"134","Nigeria","NGA","Sub-Saharan Africa","Africa",2050,2019,1,"Lower middle income",2021-03-05,"who",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,134,2021-10-01,2022-07-01,NA,2021-10-01,2022-10-01,2023-01-01
"135","Nicaragua","NIC","Latin America & Caribbean","North America",1930,2019,1,"Lower middle income",2021-03-03,"who",2021-12-29,2022-06-03,"Abdala, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Soberana02, Sputnik Light, Sputnik V",1,1,1,1,NA,NA,135,2021-06-01,2021-12-01,2021-12-01,2021-06-01,2022-10-01,2022-10-01
"136","Netherlands","NLD","Europe & Central Asia","Europe",51920,2019,4,"High income",2020-12-30,"who",2021-07-16,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2021-08-05,2,136,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"137","Norway","NOR","Europe & Central Asia","Europe",82430,2019,4,"High income",2020-12-23,"who",2021-08-12,2021-11-18,"Moderna, Pfizer/BioNTech",1,0,0,0,2022-03-25,4,137,2021-01-01,2021-01-01,2021-08-01,2021-01-01,2021-01-01,2021-01-01
"138","Nepal","NPL","South Asia","Asia",1240,2019,1,"Lower middle income",2021-01-27,"who",2022-01-24,2022-08-29,"Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,138,2021-08-01,2021-08-01,2021-08-01,2021-08-01,2021-08-01,2021-08-01
"139","Nauru","NRU","East Asia & Pacific","Oceania",15790,2019,3,"High income",2021-04-09,"equal",2021-07-20,2023-02-20,"Oxford/AstraZeneca",0,1,0,0,NA,NA,139,2021-07-01,2021-07-01,2021-07-01,2021-06-01,2021-07-01,2021-07-01
"140","New Zealand","NZL","East Asia & Pacific","Oceania",43050,2019,4,"High income",2021-02-19,"who",2021-10-05,2021-12-01,"Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,140,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01
"141","Oman","OMN","Middle East & North Africa","Asia",17810,2019,3,"High income",2020-12-28,"owid",2021-09-28,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,141,2021-12-01,2021-12-01,2021-12-01,2021-12-01,2021-12-01,2021-12-01
"142","Pakistan","PAK","South Asia","Asia",1520,2019,1,"Lower middle income",2021-02-03,"who",2022-02-16,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,142,2021-03-01,2021-06-01,2021-07-01,2021-03-01,2022-02-01,2022-03-01
"143","Panama","PAN","Latin America & Caribbean","North America",15640,2019,3,"High income",2021-01-20,"equal",2021-09-05,2022-05-13,"Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,143,2021-04-01,2021-04-01,2021-04-01,2021-07-01,2021-07-01,2021-08-01
"144","Peru","PER","Latin America & Caribbean","South America",6850,2019,3,"Upper middle income",2021-02-09,"equal",2021-10-10,2022-02-15,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,144,2022-04-01,2022-04-01,2022-04-01,2022-04-01,2022-04-01,2022-04-01
"145","Philippines","PHL","East Asia & Pacific","Asia",3760,2019,2,"Lower middle income",2021-03-01,"who",2021-12-26,NA,"Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,1,NA,NA,145,2021-03-01,2021-03-01,2021-04-01,2021-10-01,2021-10-01,2022-12-01
"146","Palau","PLW","East Asia & Pacific",NA,16220,2019,3,"Upper middle income",2021-01-03,"who",NA,NA,NA,NA,NA,NA,NA,NA,NA,146,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"147","Papua New Guinea","PNG","East Asia & Pacific","Oceania",2420,2019,2,"Lower middle income",2021-03-30,"who",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,147,2021-06-01,2021-10-01,2022-03-01,2021-06-01,NA,NA
"148","Poland","POL","Europe & Central Asia","Europe",15510,2019,3,"High income",2020-12-23,"who",2021-07-17,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,148,2021-01-01,2021-01-01,NA,2021-01-01,2021-01-01,2021-01-01
"149","Portugal","PRT","Europe & Central Asia","Europe",23180,2019,4,"High income",2020-12-23,"who",2021-07-09,2021-08-27,"Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK, Sinopharm/Beijing, Sinovac",1,1,1,1,2021-09-13,2,149,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"150","Paraguay","PRY","Latin America & Caribbean","South America",5950,2019,2,"Upper middle income",2021-02-22,"who",2021-12-10,NA,"Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V",1,1,1,0,2022-03-22,3,150,2021-03-01,2021-05-01,NA,2021-04-01,2021-08-01,2021-12-01
"151","West Bank and Gaza","PSE","Middle East & North Africa","Asia",4200,2019,2,"Upper middle income",2021-02-02,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,151,NA,NA,NA,2022-02-01,2022-02-01,NA
"152","French Polynesia","PYF","East Asia & Pacific","Oceania",19380,2000,3,"High income",2021-01-18,"who",2021-09-14,NA,"Johnson&Johnson, Pfizer/BioNTech",1,1,0,0,NA,NA,152,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"153","Qatar","QAT","Middle East & North Africa","Asia",65700,2019,4,"High income",2021-01-28,"owid",2021-05-31,2021-08-16,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,2021-06-22,16,153,NA,NA,NA,2021-03-01,2021-04-01,NA
"154","Romania","ROU","Europe & Central Asia","Europe",12700,2019,3,"High income",2020-12-28,"owid",2022-01-07,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,154,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01,2021-01-01
"155","Russian Federation","RUS","Europe & Central Asia","Europe",11190,2019,3,"Upper middle income",2020-12-15,"owid",2021-12-04,NA,"EpiVacCorona, Sputnik V",0,1,0,1,NA,NA,155,NA,NA,NA,NA,NA,NA
"156","Rwanda","RWA","Sub-Saharan Africa","Africa",820,2019,1,"Low income",2021-03-05,"equal",2022-01-27,2023-01-01,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V",1,1,1,0,NA,NA,156,2021-10-01,2021-10-01,2021-10-01,2021-10-01,2021-11-01,NA
"157","Saudi Arabia","SAU","Middle East & North Africa","Asia",27720,2019,4,"High income",2021-01-06,"equal",2021-08-30,NA,"Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,157,2021-03-01,2021-08-01,2021-10-01,2021-04-01,2021-08-01,NA
"158","Sudan","SDN","Sub-Saharan Africa","Africa",720,2019,1,"Low income",2021-03-09,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,158,2022-02-01,2022-02-01,2022-02-01,2022-02-01,NA,NA
"159","Senegal","SEN","Sub-Saharan Africa","Africa",1430,2019,1,"Lower middle income",2021-02-23,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,159,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2021-02-01,2022-09-01
"160","Singapore","SGP","East Asia & Pacific","Asia",58810,2019,4,"High income",2020-12-30,"equal",2021-07-10,2021-08-14,"Moderna, Novavax, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,0,1,1,2021-11-01,5,160,2021-01-01,2021-01-01,2021-11-01,2021-01-01,2021-01-01,2021-01-01
"161","Solomon Islands","SLB","East Asia & Pacific","Oceania",2210,2019,2,"Lower middle income",2021-03-23,"who",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,161,2021-06-01,2021-12-01,2022-05-01,2021-07-01,2022-07-01,NA
"162","Sierra Leone","SLE","Sub-Saharan Africa","Africa",850,2019,1,"Low income",2021-03-15,"who",2022-12-18,NA,"Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,NA,NA,162,2022-12-01,2022-12-01,2022-12-01,2022-12-01,NA,NA
"163","El Salvador","SLV","Latin America & Caribbean","North America",4130,2019,2,"Upper middle income",2021-02-17,"who",2021-08-27,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,NA,NA,163,2021-05-01,2021-05-01,2021-05-01,2021-05-01,2021-05-01,2021-08-01
"164","San Marino","SMR","Europe & Central Asia","Europe",43770,2019,4,"High income",2021-02-24,"who",2021-05-23,2022-03-20,"Pfizer/BioNTech, Sputnik V",1,1,0,0,2022-07-04,1,164,2021-02-01,2021-02-01,2021-05-01,2021-02-01,2021-02-01,2021-02-01
"165","Somalia","SOM","Sub-Saharan Africa","Africa",520,2019,1,"Low income",2021-03-16,"who",2023-07-25,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,165,2021-05-01,2021-06-01,2021-06-01,2021-05-01,2022-11-01,NA
"166","Serbia","SRB","Europe & Central Asia","Europe",7380,2019,3,"Upper middle income",2020-12-23,"who",2021-08-12,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,0,NA,NA,166,2021-01-01,2021-01-01,NA,2021-01-01,2021-01-01,2021-01-01
"167","South Sudan","SSD","Sub-Saharan Africa","Africa",1050,2015,1,"Low income",2021-04-06,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca",0,1,0,0,NA,NA,167,2021-10-01,2022-02-01,2022-06-01,2021-10-01,2022-04-01,2022-04-01
"168","Sao Tome and Principe","STP","Sub-Saharan Africa","Africa",1810,2019,1,"Lower middle income",2021-03-15,"who",2022-06-05,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,168,2021-11-01,2021-11-01,2021-11-01,2021-11-01,2023-06-01,NA
"169","Suriname","SUR","Latin America & Caribbean","South America",5960,2019,2,"Upper middle income",2021-02-23,"who",NA,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,169,NA,NA,NA,NA,NA,NA
"170","Slovak Republic","SVK","Europe & Central Asia","Europe",19210,2019,3,"High income",2020-12-23,"who",2021-08-29,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V",1,1,0,1,NA,NA,170,NA,NA,NA,2021-01-01,2021-01-01,2021-01-01
"171","Slovenia","SVN","Europe & Central Asia","Europe",26040,2019,4,"High income",2020-12-23,"who",2021-08-04,NA,"Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,NA,NA,171,2021-01-01,2021-01-01,NA,2021-01-01,2021-01-01,2021-01-01
"172","Sweden","SWE","Europe & Central Asia","Europe",56230,2019,4,"High income",2020-12-23,"who",2021-08-08,2022-01-23,"Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,1,2021-04-21,6,172,2021-01-01,2021-07-01,2022-05-01,2021-01-01,2021-01-01,2021-01-01
"173","Eswatini","SWZ","Sub-Saharan Africa","Africa",3650,2019,2,"Lower middle income",2021-03-19,"who",NA,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,173,2021-06-01,2021-06-01,2021-08-01,2021-06-01,2021-11-01,2022-12-01
"174","Sint Maarten (Dutch part)","SXM","Latin America & Caribbean","North America",34060,2019,4,"High income",2021-05-07,"owid",2021-07-02,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,174,NA,NA,NA,NA,NA,NA
"175","Seychelles","SYC","Sub-Saharan Africa","Africa",18700,2019,3,"High income",2021-01-10,"who",2021-04-10,2021-10-25,"Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V",0,1,1,0,NA,NA,175,NA,NA,NA,2021-10-01,2021-10-01,2021-10-01
"176","Syrian Arab Republic","SYR","Middle East & North Africa","Asia",970,2019,1,"Low income",2021-04-01,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,176,2021-10-01,NA,NA,2021-12-01,NA,NA
"177","Turks and Caicos Islands","TCA","Latin America & Caribbean","North America",26920,2019,4,"High income",2021-01-11,"who",2021-07-02,NA,"Pfizer/BioNTech",1,0,0,0,NA,NA,177,NA,NA,NA,NA,NA,NA
"178","Chad","TCD","Sub-Saharan Africa","Africa",670,2019,1,"Low income",2021-06-04,"who",NA,NA,"Sinopharm/Beijing",0,0,1,0,NA,NA,178,2021-10-01,2022-11-01,2022-11-01,2021-10-01,2023-02-01,2023-02-01
"179","Togo","TGO","Sub-Saharan Africa","Africa",860,2019,1,"Low income",2021-03-10,"who",NA,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,179,2022-01-01,2022-01-01,NA,2022-06-01,2022-12-01,2022-12-01
"180","Thailand","THA","East Asia & Pacific","Asia",7060,2019,3,"Upper middle income",2021-02-28,"who",2021-10-26,2022-03-30,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac",1,1,1,0,2022-02-03,4,180,2021-04-01,2021-05-01,2021-05-01,2021-04-01,2022-02-01,NA
"181","Tajikistan","TJK","Europe & Central Asia","Asia",1050,2019,1,"Lower middle income",2021-03-24,"who",2022-02-20,NA,"Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V",1,1,1,0,NA,NA,181,2022-01-01,2022-01-01,2022-01-01,NA,NA,NA
"182","Turkmenistan","TKM","Europe & Central Asia","Asia",6450,2019,2,"Upper middle income",2021-02-24,"who",2022-03-06,2023-08-06,"EpiVacCorona, Oxford/AstraZeneca, QazVac, Sinopharm/Beijing, Sputnik V, ZF2001",0,1,1,1,NA,NA,182,2021-02-01,2021-11-01,NA,2021-02-01,NA,NA
"183","Timor-Leste","TLS","East Asia & Pacific","Asia",2180,2019,2,"Lower middle income",2021-04-07,"who",2022-01-04,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,183,2021-08-01,2021-08-01,2021-08-01,2021-08-01,2021-08-01,2021-08-01
"184","Tonga","TON","East Asia & Pacific","Oceania",4940,2019,2,"Upper middle income",2021-04-14,"who",2021-11-22,2022-07-25,"Oxford/AstraZeneca",0,1,0,0,NA,NA,184,2021-07-01,2021-07-01,2021-08-01,2021-07-01,2021-07-01,2021-10-01
"185","Trinidad and Tobago","TTO","Latin America & Caribbean","North America",17540,2019,3,"High income",2021-02-17,"who",2021-11-06,NA,"Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,185,2021-03-01,NA,NA,NA,NA,NA
"186","Tunisia","TUN","Middle East & North Africa","Africa",3590,2019,2,"Lower middle income",2021-03-13,"equal",2021-11-22,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,186,NA,NA,NA,2022-11-01,2022-11-01,2022-11-01
"187","Turkiye","TUR","Europe & Central Asia","Asia",9800,2019,3,"Upper middle income",2021-01-14,"owid",2021-08-19,NA,"Pfizer/BioNTech, Sinovac, Turkovac",1,0,1,0,2022-03-19,3,187,NA,NA,NA,NA,NA,NA
"188","Tuvalu","TUV","East Asia & Pacific","Oceania",6880,2019,3,"Upper middle income",2021-04-13,"who",2021-09-10,2022-07-21,"Oxford/AstraZeneca",0,1,0,0,NA,NA,188,2022-02-01,2022-02-01,2022-02-01,2022-02-01,NA,NA
"189","Tanzania","TZA","Sub-Saharan Africa","Africa",1050,2019,1,"Lower middle income",2021-07-28,"who",2022-11-27,NA,"Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing",1,1,1,0,NA,NA,189,2021-11-01,2021-11-01,NA,2021-11-01,2022-12-01,2022-12-01
"190","Uganda","UGA","Sub-Saharan Africa","Africa",810,2019,1,"Low income",2021-03-10,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,190,2021-11-01,2021-11-01,2022-04-01,2021-11-01,NA,NA
"191","Ukraine","UKR","Europe & Central Asia","Europe",3270,2019,2,"Lower middle income",2021-02-24,"who",NA,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,191,2021-02-01,2021-02-01,NA,2021-02-01,NA,NA
"192","Uruguay","URY","Latin America & Caribbean","South America",18390,2019,3,"High income",2021-02-27,"equal",2021-06-18,2021-08-12,"Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac",1,1,1,0,NA,NA,192,2021-07-01,2021-07-01,2021-07-01,2021-03-01,2021-07-01,2021-11-01
"193","United States","USA","North America","North America",66220,2019,4,"High income",2020-12-13,"owid",2021-05-14,NA,"Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech",1,1,0,1,2021-02-18,135,193,NA,NA,NA,2021-03-01,2021-03-01,2021-06-01
"194","Uzbekistan","UZB","Europe & Central Asia","Asia",2150,2019,1,"Lower middle income",2021-04-06,"owid",2022-03-13,NA,"Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik Light, Sputnik V, ZF2001",1,1,1,1,NA,NA,194,2021-04-01,2021-08-01,2022-05-01,2021-04-01,NA,NA
"195","St. Vincent and the Grenadines","VCT","Latin America & Caribbean","North America",8700,2019,3,"Upper middle income",2021-02-01,"who",NA,NA,"Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik Light, Sputnik V",1,1,0,0,NA,NA,195,2021-03-01,2021-03-01,NA,2021-03-01,NA,NA
"196","Venezuela, RB","VEN","Latin America & Caribbean","South America",12990,2014,3,NA,2021-02-22,"who",2021-12-17,NA,"Abdala, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V",0,1,1,1,NA,NA,196,2021-03-01,2021-08-01,2021-08-01,2021-03-01,2021-09-01,2021-09-01
"197","Viet Nam","VNM","East Asia & Pacific","Asia",3290,2019,2,"Lower middle income",2021-03-08,"who",2021-12-02,2022-01-13,"Abdala, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V",1,1,1,1,NA,NA,197,2021-04-01,2021-07-01,2021-07-01,2021-08-01,2022-02-01,2022-03-01
"198","Vanuatu","VUT","East Asia & Pacific","Oceania",3740,2019,2,"Lower middle income",2021-06-02,"who",2022-10-17,NA,"Oxford/AstraZeneca",0,1,0,0,NA,NA,198,2021-07-01,2021-08-01,2021-08-01,2021-07-01,2022-01-01,2022-04-01
"199","Samoa","WSM","East Asia & Pacific","Oceania",4270,2019,2,"Lower middle income",2021-04-18,"who",2021-11-30,2022-05-02,"Oxford/AstraZeneca",0,1,0,0,NA,NA,199,2022-02-01,2022-02-01,2022-02-01,2022-02-01,2022-02-01,2022-02-01
"200","Kosovo","XKX","Europe & Central Asia","Europe",4640,2019,2,"Upper middle income",2021-03-31,"who",2021-10-27,NA,"Oxford/AstraZeneca, Pfizer/BioNTech",1,1,0,0,NA,NA,200,NA,NA,NA,NA,NA,NA
"201","Yemen, Rep.","YEM","Middle East & North Africa","Asia",740,2018,1,"Low income",2021-04-20,"who",NA,NA,"CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V",1,1,1,0,NA,NA,201,2021-06-01,NA,NA,2021-06-01,NA,NA
"202","South Africa","ZAF","Sub-Saharan Africa","Africa",6570,2019,3,"Upper middle income",2021-02-17,"who",NA,NA,"Johnson&Johnson, Pfizer/BioNTech",1,1,0,0,2021-12-20,5,202,NA,NA,NA,2021-02-01,2021-02-01,2021-02-01
"203","Zambia","ZMB","Sub-Saharan Africa","Africa",1380,2019,1,"Lower middle income",2021-04-14,"who",2022-10-27,NA,"Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing",0,1,1,0,2022-06-08,1,203,2021-09-01,2021-09-01,2021-12-01,2021-10-01,2023-01-01,NA
"204","Zimbabwe","ZWE","Sub-Saharan Africa","Africa",2170,2019,1,"Lower middle income",2021-02-18,"who",NA,NA,"Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V",0,1,1,0,NA,NA,204,NA,NA,NA,NA,NA,NA
